Recently, Jingwei Shida Medical Technology Co., Ltd. ("Jingwei Shida") announced the completion of a new financing round exceeding RMB 100 million, co-led by Efung Zhuohua Fund, Huabin Fengtai Private Equity Fund, and Changfei Industrial Fund. The funds will be primarily used for continued R&D, scaled production, clinical application promotion, and global commercialization of confocal microscopy endoscopy products.

As a high-end medical device enterprise focused on precision diagnosis and treatment of early-stage tumors, Jingwei Shida has remained committed to its vision and mission. After two decades of deep cultivation through integrated "industry-academia-research-medicine-inspection" collaboration and supported by more than ten National Key R&D Programs, the company has obtained multiple confocal microscopy endoscopy registration certificates and received national-level scientific and technological achievement certification from the Ministry of Industry and Information Technology, with technology reaching internationally advanced levels.

The company has fully mastered key core technologies for domestic confocal microscopy endoscopy, spanning from critical materials and core components to complete system integration, breaking free from dependence on imported equipment and technology. It has achieved "independent control, replicability, and scalability" for domestic confocal microscopy endoscopy. Furthermore, the company has overcome manufacturing barriers, built a complete independent industrial chain for confocal microscopy endoscopy, and established a world-leading scaled manufacturing base for confocal microscopy endoscopy. It operates the world's largest scaled production and manufacturing center for confocal microscopy endoscopy, committed to advancing the domestic production and internationalization of confocal microscopy endoscopy and the global export of Chinese technical standards.

Looking ahead, Jingwei Shida will continue to deepen its "industry-academia-research-medicine-inspection" integration, persistently advancing iterative innovation of key technologies and optimization of production costs, so that "internationally advanced, fully independent, clinically accessible" cellular-level endoscopy technology truly achieves "domestic pricing with international quality."